<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424136</url>
  </required_header>
  <id_info>
    <org_study_id>PEAAP (14/12/12/4.12)</org_study_id>
    <nct_id>NCT02424136</nct_id>
  </id_info>
  <brief_title>PEAnut Anaphylaxis Predictors</brief_title>
  <acronym>PEAAP</acronym>
  <official_title>PEAnut Anaphylaxis Predictors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Hunter Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunter Medical Research Institute, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Newcastle, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunter Childrens Research Foundation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aerocrine AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>John Hunter Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peanut allergy can be life-threatening. Current diagnostic techniques for peanut allergy have
      high sensitivity, but not high specificity. This clinical trial will test the validity of a
      novel blood biomarker (compared with current testing) as a diagnostic predictor of
      anaphylaxis to peanut.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children aged 6-17 years with suspected peanut allergy will be invited to participate in the
      study.

      They will have a questionnaire, a skin prick test to peanut, 2 breathing tests (spirometry
      and fraction of exhaled nitric oxide (FeNO)), and a blood test (specific peanut antibodies,
      allergic immune responses - including the novel blood biomarker - and genetic testing to
      identify novel potential molecular and genetic markers of food allergy in the future. The
      genetic testing component will be optional).

      The final step is an open label peanut food challenge with incremental doses of peanut,
      (routine practise) as per the Australasian Society of Clinical Immunology and Allergy (ASCIA)
      food challenge protocol.The endpoints in the food challenge will be signs of allergy or
      anaphylaxis as per PRACTicing ALLergology (PRACTALL) consensus report for oral food
      challenges OR completion of the ASCIA food challenge protocol.

      Outcome: The primary outcome of the project is to confirm that a novel blood biomarker has a
      higher diagnostic accuracy as compared to current best testing in predicting anaphylaxis at
      open label peanut challenge.

      Secondary outcome: Will be to determine the value of the biomarker, FeNO and Ara h2 specific
      Immunoglobulin E (sIgE) (individually and in combination) at predicting anaphylaxis or
      clinical allergy at open label peanut challenge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood biomarker predicting anaphylaxis at peanut food challenge</measure>
    <time_frame>At completion of peanut food challenge</time_frame>
    <description>The primary outcome of the project is to confirm that a novel blood biomarker has a higher diagnostic accuracy as compared to current best testing in predicting anaphylaxis at open label peanut challenge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood biomarker in combination with FeNO, and/or Ara h2 sIgE predicting anaphylaxis at peanut food challenge</measure>
    <time_frame>At completion of peanut food challenge</time_frame>
    <description>The secondary outcome will be to determine the value of the biomarker, FeNO and Ara h2 sIgE (individually and in combination) at predicting anaphylaxis or clinical allergy at open label peanut challenge.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Peanut Hypersensitivity</condition>
  <condition>Anaphylaxis</condition>
  <arm_group>
    <arm_group_label>Entire group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children aged 6-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>5 minute questionnaire focused on symptoms of allergic disease</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peanut Skin prick test</intervention_name>
    <description>Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fraction of exhaled nitric oxide</intervention_name>
    <description>Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Measurement of lung flows/volumes, according to ATS/ERS standardised procedures</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum Peanut and Ara h2 specific immunoglobulin E</intervention_name>
    <description>Peanut and Ara h2 specific IgE antibodies</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of blood biomarker</intervention_name>
    <description>Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peanut food challenge</intervention_name>
    <description>Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report</description>
    <arm_group_label>Entire group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 6 - 17 years with an allergy to peanut and require peanut challenge to
             confirm peanut allergy.

        Exclusion Criteria:

          -  Children with Peanut Skin Prick Test (SPT) wheal size greater than 10mm as these
             children are likely to have clinical peanut allergy (no clinical indication for food
             challenge).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Mattes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Hunter Children's Hospital, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joerg Mattes, MD</last_name>
    <phone>+61 2 49855277</phone>
    <email>joerg.mattes@hnehealth.nsw.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rani Bhatia, MD</last_name>
    <phone>+61 2 49213676</phone>
    <email>rani.bhatia@hnehealth.nsw.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Hunter Children's Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Mattes, MD</last_name>
      <phone>+ 61 2 4985 5277</phone>
      <email>Joerg.Mattes@hnehealth.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Joerg Mattes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.allergy.org.au/images/stories/pospapers/cp/ASCIA_HP_food_challenge_protocol_peanut_2015.pdf</url>
    <description>ASCIA Food Challenge Protocols - Peanut</description>
  </link>
  <link>
    <url>http://www.allergy.org.au/health-professionals/papers/skin-prick-testing</url>
    <description>ASCIA Skin prick testing for the diagnosis of allergic disease. A manual for practitioners.</description>
  </link>
  <reference>
    <citation>Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, Werfel T, Chinchilli VM. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &amp; Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 Dec;130(6):1260-74. doi: 10.1016/j.jaci.2012.10.017.</citation>
    <PMID>23195525</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <reference>
    <citation>American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30.</citation>
    <PMID>15817806</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Anaphylaxis</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

